Do analysts recommend AMGN or PFE?

Amgen currently has a consensus price target of $381.68, indicating a potential upside of 1.60%. Pfizer has a consensus price target of $28.39, indicating a potential upside of 3.14%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Amgen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 3 Sell rating(s) 15 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.33 Pfizer 2 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.19

Which has preferable valuation and earnings, AMGN or PFE?

Pfizer has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $36.75B 5.53 $7.71B $16.09 23.35 Pfizer $63.70B 2.46 $7.77B $0.76 36.22

Is AMGN or PFE more profitable?

Amgen has a net margin of 22.95% compared to Pfizer's net margin of 6.80%. Amgen's return on equity of 124.14% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 22.95% 124.14% 13.18% Pfizer 6.80% 19.63% 8.46%

Does the media refer more to AMGN or PFE?

In the previous week, Amgen had 10 more articles in the media than Pfizer. MarketBeat recorded 42 mentions for Amgen and 32 mentions for Pfizer. Pfizer's average media sentiment score of 0.73 beat Amgen's score of 0.22 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 11 Very Positive mention(s) 7 Positive mention(s) 15 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral Pfizer 16 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Is GILD or PFE more profitable?

Pfizer has a net margin of 6.80% compared to Gilead Sciences' net margin of -10.64%. Pfizer's return on equity of 19.63% beat Gilead Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% Pfizer 6.80% 19.63% 8.46%

Does the media refer more to GILD or PFE?

In the previous week, Gilead Sciences and Gilead Sciences both had 32 articles in the media. Gilead Sciences' average media sentiment score of 1.12 beat Pfizer's score of 0.73 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 21 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Pfizer 16 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MRNA or PFE?

Pfizer has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $2.21B 25.97 -$2.82B -$7.99 N/A Pfizer $63.70B 2.46 $7.77B $0.76 36.22

Is MRNA or PFE more profitable?

Pfizer has a net margin of 6.80% compared to Moderna's net margin of -141.43%. Pfizer's return on equity of 19.63% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Pfizer 6.80% 19.63% 8.46%

Does the media prefer MRNA or PFE?

In the previous week, Pfizer had 6 more articles in the media than Moderna. MarketBeat recorded 32 mentions for Pfizer and 26 mentions for Moderna. Pfizer's average media sentiment score of 0.73 beat Moderna's score of 0.38 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 8 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Pfizer 16 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings and valuation, NVAX or PFE?

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $413.80M 3.68 $440.30M -$1.52 N/A Pfizer $63.70B 2.46 $7.77B $0.76 36.22

Is NVAX or PFE more profitable?

Pfizer has a net margin of 6.80% compared to Novavax's net margin of -59.87%. Pfizer's return on equity of 19.63% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Pfizer 6.80% 19.63% 8.46%

Does the media prefer NVAX or PFE?

In the previous week, Pfizer had 17 more articles in the media than Novavax. MarketBeat recorded 32 mentions for Pfizer and 15 mentions for Novavax. Pfizer's average media sentiment score of 0.73 beat Novavax's score of 0.44 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Pfizer 16 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ABBV or PFE?

Pfizer has higher revenue and earnings than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 7.60 $4.23B $3.54 74.28 Pfizer $63.70B 2.46 $7.77B $0.76 36.22

Is ABBV or PFE more profitable?

AbbVie has a net margin of 9.80% compared to Pfizer's net margin of 6.80%. Pfizer's return on equity of 19.63% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 9.80% -422.07% 14.34% Pfizer 6.80% 19.63% 8.46%

Does the media prefer ABBV or PFE?

In the previous week, AbbVie had 45 more articles in the media than Pfizer. MarketBeat recorded 77 mentions for AbbVie and 32 mentions for Pfizer. AbbVie's average media sentiment score of 1.24 beat Pfizer's score of 0.73 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 53 Very Positive mention(s) 10 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 16 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Pfizer (PFE) Competitors

$27.52 -0.20 (-0.70%)

Closing price 03:59 PM Eastern

Extended Trading

$27.52 0.00 (-0.02%)

As of 04:45 PM Eastern

Compare

PFE vs. AMGN, GILD, MRNA, NVAX, and ABBV

Should you buy Pfizer stock or one of its competitors? Pfizer's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Pfizer compare to Amgen?

Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amgen currently has a consensus price target of $381.68, indicating a potential upside of 1.60%. Pfizer has a consensus price target of $28.39, indicating a potential upside of 3.14%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.33
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.7%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.2%. Amgen pays out 62.6% of its earnings in the form of a dividend. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Amgen had 10 more articles in the media than Pfizer. MarketBeat recorded 42 mentions for Amgen and 32 mentions for Pfizer. Pfizer's average media sentiment score of 0.73 beat Amgen's score of 0.22 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	11 Very Positive mention(s)	7 Positive mention(s)	15 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral
Pfizer	16 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

Amgen has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Pfizer has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	5.53	$7.71B	$16.09	23.35
Pfizer	$63.70B	2.46	$7.77B	$0.76	36.22

Amgen has a net margin of 22.95% compared to Pfizer's net margin of 6.80%. Amgen's return on equity of 124.14% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
Pfizer	6.80%	19.63%	8.46%

Summary

Amgen beats Pfizer on 12 of the 19 factors compared between the two stocks.

How does Pfizer compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Gilead Sciences currently has a consensus price target of $158.78, suggesting a potential upside of 8.53%. Pfizer has a consensus price target of $28.39, suggesting a potential upside of 3.14%. Given Gilead Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Gilead Sciences is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.86
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Gilead Sciences has higher earnings, but lower revenue than Pfizer. Gilead Sciences is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	6.16	$8.51B	-$2.67	N/A
Pfizer	$63.70B	2.46	$7.77B	$0.76	36.22

Pfizer has a net margin of 6.80% compared to Gilead Sciences' net margin of -10.64%. Pfizer's return on equity of 19.63% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Pfizer	6.80%	19.63%	8.46%

Gilead Sciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.2%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.2%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 10 consecutive years and Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Gilead Sciences and Gilead Sciences both had 32 articles in the media. Gilead Sciences' average media sentiment score of 1.12 beat Pfizer's score of 0.73 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	21 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Pfizer	16 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Pfizer beats Gilead Sciences on 10 of the 18 factors compared between the two stocks.

How does Pfizer compare to Moderna?

Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Moderna currently has a consensus target price of $76.72, suggesting a potential downside of 46.64%. Pfizer has a consensus target price of $28.39, suggesting a potential upside of 3.14%. Given Pfizer's stronger consensus rating and higher probable upside, analysts plainly believe Pfizer is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

In the previous week, Pfizer had 6 more articles in the media than Moderna. MarketBeat recorded 32 mentions for Pfizer and 26 mentions for Moderna. Pfizer's average media sentiment score of 0.73 beat Moderna's score of 0.38 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	8 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pfizer	16 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

75.3% of Moderna shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 0.6% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Moderna has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Pfizer has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.21B	25.97	-$2.82B	-$7.99	N/A
Pfizer	$63.70B	2.46	$7.77B	$0.76	36.22

Pfizer has a net margin of 6.80% compared to Moderna's net margin of -141.43%. Pfizer's return on equity of 19.63% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Pfizer	6.80%	19.63%	8.46%

Summary

Pfizer beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Pfizer compare to Novavax?

Novavax (NASDAQ:NVAX) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Pfizer had 17 more articles in the media than Novavax. MarketBeat recorded 32 mentions for Pfizer and 15 mentions for Novavax. Pfizer's average media sentiment score of 0.73 beat Novavax's score of 0.44 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pfizer	16 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

53.0% of Novavax shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$413.80M	3.68	$440.30M	-$1.52	N/A
Pfizer	$63.70B	2.46	$7.77B	$0.76	36.22

Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Novavax presently has a consensus price target of $14.00, suggesting a potential upside of 51.68%. Pfizer has a consensus price target of $28.39, suggesting a potential upside of 3.14%. Given Novavax's stronger consensus rating and higher possible upside, analysts plainly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Pfizer has a net margin of 6.80% compared to Novavax's net margin of -59.87%. Pfizer's return on equity of 19.63% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Pfizer	6.80%	19.63%	8.46%

Summary

Pfizer beats Novavax on 11 of the 17 factors compared between the two stocks.

How does Pfizer compare to AbbVie?

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Pfizer has higher revenue and earnings than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.60	$4.23B	$3.54	74.28
Pfizer	$63.70B	2.46	$7.77B	$0.76	36.22

AbbVie has a net margin of 9.80% compared to Pfizer's net margin of 6.80%. Pfizer's return on equity of 19.63% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Pfizer	6.80%	19.63%	8.46%

AbbVie has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.2%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 53 consecutive years and Pfizer has raised its dividend for 16 consecutive years.

In the previous week, AbbVie had 45 more articles in the media than Pfizer. MarketBeat recorded 77 mentions for AbbVie and 32 mentions for Pfizer. AbbVie's average media sentiment score of 1.24 beat Pfizer's score of 0.73 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	53 Very Positive mention(s)	10 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	16 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

AbbVie currently has a consensus target price of $276.64, suggesting a potential upside of 5.21%. Pfizer has a consensus target price of $28.39, suggesting a potential upside of 3.14%. Given AbbVie's stronger consensus rating and higher probable upside, equities analysts clearly believe AbbVie is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

AbbVie beats Pfizer on 14 of the 20 factors compared between the two stocks.

Get Pfizer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFE vs. The Competition

Export

Metric	Pfizer	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$156.88B	$12.44B	$7.16B	$23.08B
Dividend Yield	6.20%	2.64%	2.57%	3.58%
P/E Ratio	36.22	792.10	273.41	28.42
Price / Sales	2.46	763.25	674.51	88.62
Price / Cash	6.30	14.86	28.42	19.47
Price / Book	1.80	10.40	10.38	4.71
Net Income	$7.77B	$2.83B	$3.49B	$1.07B
7 Day Performance	-0.92%	-3.28%	-2.17%	-2.42%
1 Month Performance	2.80%	0.80%	-0.37%	-4.27%
1 Year Performance	14.78%	3.62%	19.18%	8.87%

Pfizer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFE Pfizer	2.9611 of 5 stars	$27.53 -0.7%	$28.39 +3.1%	+16.0%	$156.88B	$63.70B	36.22	75,000	Trending News Analyst Upgrade
AMGN Amgen	3.5665 of 5 stars	$437.23 flat	$381.68 -12.7%	+38.0%	$236.38B	$36.75B	27.17	31,500	Trending News
GILD Gilead Sciences	3.7602 of 5 stars	$150.99 flat	$158.04 +4.7%	+27.8%	$187.23B	$29.44B	N/A	17,000	Trending News Options Volume
MRNA Moderna	2.1059 of 5 stars	$145.55 flat	$76.72 -47.3%	+523.9%	$58.11B	$1.94B	N/A	4,700	Trending News Insider Trade
NVAX Novavax	2.2376 of 5 stars	$10.22 flat	$14.00 +37.0%	+20.2%	$1.69B	$1.12B	N/A	1,990	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PFE) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Competitors